The combination of taxanes and anthracyclines has been recommended as the preferred regimen for patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer, especially those with locally advanced breast cancer (LABC) or high risk EBC, who were pursuing rapid tumor shrinkage through neoadjuvant chemotherapy [3]. The gene discussed is ERBB2; the disease is breast cancer.